Get the Stockscreener App
55.93
1.29%
-0.73
After Hours:
55.93
Haemonetics Corp stock is traded at $55.93, with a volume of 495.68K.
It is down -1.29% in the last 24 hours and down -10.28% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$56.66
Open:
$57.11
24h Volume:
495.68K
Relative Volume:
0.61
Market Cap:
$2.60B
Revenue:
$1.32B
Net Income/Loss:
$175.44M
P/E Ratio:
15.37
EPS:
3.6395
Net Cash Flow:
$308.08M
1W Performance:
-6.03%
1M Performance:
-10.28%
6M Performance:
+17.33%
1Y Performance:
-11.71%
1-Day Range:
$55.12
$57.72
1-Week Range:
$55.12
$60.93
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
55.93 | 2.63B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year - Yahoo Finance
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
HAE Stock Price, Quote & Chart | HAEMONETICS CORP/MASS (NYSE:HAE) - ChartMill
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Haemonetics Corporation $HAE Shares Purchased by Invenomic Capital Management LP - MarketBeat
Haemonetics Corp Stock (ISIN: US4041191090) Faces Pressure Amid Hospital Recovery and Debt Concerns - AD HOC NEWS
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions? - simplywall.st
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning? - Yahoo Finance
Aristotle Capital Boston LLC Increases Stock Position in Haemonetics Corporation $HAE - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $70 - 富途牛牛
Haemonetics Corp Stock (ISIN: US4041191090) Expands Hospital Portfolio Amid Valuation Discount and A - AD HOC NEWS
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $70 - 富途牛牛
Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation - simplywall.st
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics - Markets Mojo
Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC - MarketBeat
Haemonetics price target lowered to $70 from $75 at Citi - TipRanks
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Haemonetics (HAE) Valuation After Recent Share Price Pullback - Yahoo Finance
Elo Mutual Pension Insurance Co Takes $829,000 Position in Haemonetics Corporation $HAE - MarketBeat
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack - Yahoo Finance
A Review of Q4 Earnings for Medical Devices & Supplies Specialty Stocks: Comparing Haemonetics (NYSE:HAE) to Its Competitors - Bitget
Haemonetics Wins FDA Nod For Persona PLUS Plasma Growth Opportunity - simplywall.st
Haemonetics Corporation $HAE Shares Sold by Fisher Asset Management LLC - MarketBeat
North Peak group discloses 5.1% stake in Haemonetics (NYSE: HAE) - Stock Titan
Haemonetics Repays $300 Million Convertible Senior Notes Due 2026 - marketscreener.com
William Blair Investment Management LLC Buys 57,332 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp repays outstanding 0.00% convertible senior notesSEC filing - marketscreener.com
Haemonetics repays $300 million convertible notes at maturity By Investing.com - Investing.com Canada
Haemonetics repays $300 million convertible notes at maturity - Investing.com
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure - TipRanks
Haemonetics repays $300M 0.00% convertible notes due 2026 in cash - TradingView
Haemonetics (NYSE: HAE) retires $300M zero-coupon 2026 convertible notes in cash - Stock Titan
Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System - simplywall.st
Haemonetics at Raymond James: Strategic Growth and Challenges - Investing.com Nigeria
Haemonetics at Raymond James: Strategic Growth and Challenges By Investing.com - Investing.com Australia
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):